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ABSTRACT
Objectives: Public programs ﬁnance a large share of the US pharmaceu-
tical expenditures. To date, there are not guidelines for estimating the cost
of drugs ﬁnanced by US public programs. The objective of this study was
to provide standards for estimating the cost of drugs ﬁnanced by US public
programs for utilization in pharmacoeconomic evaluations.
Methods: This report was prepared by the ISPOR Task Force on Good
Research Practices—Use of Drug Costs for Cost-Effectiveness Analysis
Medicare, Medicaid, and other US Government Payers Subgroup. The
Subgroup was convened to assess the methodological and practical issues
confronted by researchers when estimating the cost of drugs ﬁnanced by
US public programs, and to propose standards for more transparent,
accurate and consistent costing methods.
Results: The Subgroup proposed these recommendations: 1) researchers
must consider regulation requirements that affect the drug cost paid by
public programs; 2) drug cost must represent the actual acquisition cost,
incorporating any rebates or discounts; 3) transparency with respect to
cost inputs must be ensured; 4) inclusion of the public program’s perspec-
tive is recommended; 5) high cost drugs require special attention, parti-
cularly when drugs represent a signiﬁcant proportion of health-care
expenditures for a speciﬁc disease; and 6) because of variations across
public programs, sensitivity analyses for actual acquisition cost, real-world
adherence, and generics availability are warranted. Speciﬁc recommenda-
tions also were proposed for the Medicare and Medicaid programs.
Conclusions: As pharmacoeconomic evaluations for coverage decisions
made by US public programs grows, the need for precise and consistent
estimation of drug costs is warranted. Application of the proposed rec-
ommendations will allow researchers to include accurate and unbiased
cost estimates in pharmacoeconomic evaluations.
Keywords: cost study, drug cost, Medicaid, Medicare, pharmacoeco-
nomic.
Background to theTask Force
The ISPOR Task Force on Good Research Practices—Use of
Drug Costs for Cost-Effectiveness Analysis (DCTF) was recom-
mended by the ISPOR Health Science Policy Council on Decem-
ber 13, 2004 and approved by the ISPOR Board of Directors
May 15, 2005. Because how drug costs should be measured for
cost-effectiveness analyses (CEAs) depend on the perspectives,
ﬁve Task Force subgroups were created to develop drug costs
standards from the societal, managed care, US government,
industry, and international perspective. This report is Part IV: a
US government perspective (one of six reports from this ISPOR
Task Force on Good Research Practices—Use of DCTF. The
other reports (Part I: issues and recommendations; Part II: a
societal perspective; Part III: managed care; Part V: industry
perspective; and Part VI: international perspective) are also
published in this issue of Value in Health (Volume 13, Issue 1).
This DCTF subgroup met to develop core assumptions and an
outline before preparing a draft report. The Task Force sub-
groups held open forums and/or group leader breakfast meetings
at the ISPOR Annual International Meetings and European Con-
gresses. The draft report was circulated to 174 Task Force
primary reviewers (who were self-identiﬁed from a broad range
of perspectives). Following this review, a new draft was prepared
and made accessible for broader review by all ISPOR members.
Comments for these reports by Task Force primary reviewers and
ISPOR membership are published at the ISPOR website. All
opinions reﬂect those of the authors and not necessarily their
afﬁliations.
Introduction
This article is part of a series that address the topic of estimating
drug costs for pharmacoeconomic and outcomes research
studies. The goal of this DCTF Subgroup was to focus on drug
cost estimation from the perspectives of Medicare, Medicaid, and
other government payers in the United States for purposes of
conducting pharmacoeconomic and cost studies.
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Drug Expenditures and Costs in the Public
Sectors of the United States
Public pharmaceutical spending represents expenditures by
Federal, State, and local governments. The largest public phar-
maceutical programs are Medicare, Medicaid, and the State Chil-
dren’s Health Insurance Program. These programs are run by
the Federal agency Centers for Medicare & Medicaid Services
(CMS); however, Medicaid is administered by the States within
broad Federal guidelines. Other public pharmaceutical programs
include the Department of Defense, the Department of Veterans’
Affairs (VA), Workers’ Compensation programs, and State-only
general assistance programs. The public sector also funds other
programs that purchase pharmaceuticals including: maternal and
child health services, school health programs, public hospitals
and clinics, Indian health-care services, migrant health-care ser-
vices, substance abuse and mental health activities, and medically
related vocational rehabilitation services [1].
In 2007, the CMS served approximately 93 million beneﬁ-
ciaries outlaying approximately $570.5 billion dollars [2]. CMS
provides pharmaceutical coverage through its various beneﬁt
programs of Medicare and Medicaid. A description of the Medi-
caid and Medicare programs, including the prescription drug
components, are summarized in Table 1. In addition to Medicare
and Medicaid, there are a number of other public payers in the
United States. In 2008, CMS projects that 46% of health-care
expenditures and 35% of drug expenditures in the United States
will be paid by public payers [3]. This is a substantial increase
from prior years and, as a result, estimating pharmaceutical
expenditures and the value of prescription medicines from a US
public payer perspective is increasingly important.
As the public sector pays for a greater proportion of drug
expenditures, there is an increasing desire for price transparency
and more focus on discriminatory pricing. Discriminatory
pricing occurs when pharmaceutical companies charge different
prices to different groups of consumers (e.g., Medicare and
Medicaid enrollees vs. enrollees of a managed care organization
[MCO]) for identical pharmaceuticals. Traditionally, average
wholesale price (AWP) was the most commonly used mechanism
for pharmacy reimbursement, but the wide variations in dis-
counts of AWP led to many controversies regarding the differ-
ences in pharmaceutical prices across payers.
Congress introduced a new average sales price (ASP) to stan-
dardize the reimbursement process and to minimize variation in
pharmaceutical prices paid by Medicare for certain medications
used in physician ofﬁces beginning January 1, 2005 [4]. Congress
has also approved the use of the average manufacturer price
(AMP) for Medicaid fee-for-service outpatient drug reimburse-
ment. The ASP is a computed average manufacturer transaction
price, calculated using sales data for all multiple source products
available in the market for that drug, i.e., the payments that
manufacturers received for their products. It is the weighted
average of all non-Federal sales to wholesalers and is net of
charge backs, discounts, rebates, and other beneﬁts tied to the
purchase of the drug product, whether it is paid to the wholesaler
or to the retailer [4]. Thus, the ASP for drug products that have
generic competition is very low. The ASP and the AMP were
expected to be the future established reimbursement basis for
Federal and possible even non-Federal insurers, but the use of
AMP for Medicaid outpatient pharmacy reimbursement has been
challenged. Thus, researchers and decision-makers need to better
understand the mechanisms and implications of the evolving
pharmaceutical cost structure for public payers. In this article, we
aim to provide guidance for estimating drug costs to be used in
cost-effectiveness and health economics studies from a public
payer perspective.
Table 1 Features of Medicare and Medicaid programs [10,25,26]
Feature Medicare Medicaid
1. Enacted in 1965 Federal health insurance program covers acute inpatient
(through Part A) and post–acute outpatient care (through
Part B); and since 2006 covers outpatient prescription
drugs (through prescription drug insurance, Part D).
Federal and state joint health insurance program; provides
health and long-term care coverage, and prescription drugs,
which are covered although not mandated.
2. Financing Federal government funding through taxes, income and
premiums.
Federal and state spending with Federal government funding
57% in 2006. States pay back Medicare for Part D
prescription drug coverage for their dual eligible.
3. Eligibility Aged 65 and above, disabled and those with end stage renal
disease of any age; 44 million elderly and disabled
Americans in 2006.
Welfare population of a particular Federal poverty level (single
parents with dependent children, aged, blind, disabled); over
52 million low-income people including over 6 million
Medicare beneﬁciaries, the dual eligible in 2006.
4. Patient cost sharing and
variation in coverage
All costs vary by the type of service, and the plan the
beneﬁciary enrolls into and the level and duration of
service received.
For traditional Parts A and B services, patients may or may
not pay a premium and deductible and also may have a
copayment or pay coinsurance.
Compared with Part D beneﬁciaries above 150% of the
Federal poverty level (FPL), those below the 150% FPL level
may pay a lower premium or may not pay a premium and
may have lower or no copayments or coinsurance. Part D
beneﬁciaries who are below the 150% of the Federal
poverty level (FPL) include dual eligibles on Medicare and
Medicaid who will not have gaps in coverage; however part
D beneﬁciaries above the 150% FPL will have gaps in
coverage unless they enroll in high cost plans that cover
drugs in the donut hole.
State Medicaid Programs are prohibited from imposing
premiums or cost sharing for emergency room visits, family
planning services, hospice care, and preferred drugs on
certain groups including institutionalized persons, pregnant
women, children and women in breast or cervical cancer
programs.
5. Cost containment
measures
Drug utilization controls by private drug plans—use of
formulary based tiered prescription drug beneﬁt structure
by competing private insurance plans, manufacturer rebates,
and reducing provider reimbursement.
Preferred drug lists, manufacturer rebates, State’s maximum
allowable cost, disease management, freezing or reducing
provider reimbursements, reducing pharmacy dispensing
fees, and increasing patient copayments.
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Medicaid Program
Medicaid is a government-sponsored health insurance program
that is administered at the state level and is available to certain
low-income individuals/families that ﬁt within an eligible group
recognized by both Federal and State laws. Medicaid does not
reimburse the beneﬁciaries directly. Instead, it reimburses their
health-care providers directly. Depending on the state of resi-
dence and the eligibility status, the beneﬁciary may be required to
provide a copayment for certain medical services and drugs.
A wide variety of individuals/families are covered by Medic-
aid. Requirements that must be met to be eligible for Medicaid
coverage may include: whether one is pregnant, disabled, blind,
or aged; the individual’s income and resources; and whether one
is a US citizen or a lawfully admitted immigrant. The rules
concerning income and resources vary from state to state and
from group to group. In addition, there are special rules for those
who live in nursing homes and for disabled children living at
home.
The Medicaid program pays for inpatient and outpatient
prescription drugs. States maintain autonomy in setting the phar-
macy payment rates for outpatient prescription drugs [5]. There
are three components in the Medicaid drugs cost: 1) the esti-
mated drug acquisition cost that the state pays the pharmacies; 2)
the dispensing fee that the state pays the pharmacies; and 3) the
drug rebates that the Medicaid Program receives from the drug
manufacturers [6]. This rebates applies only to outpatient drugs
purchased by the program on a fee-for-service basis [6]. When
drugs are purchased through capitated MCOs, the MCOs may
negotiate their own rebates and discounts [6]. Some states nego-
tiate supplemental rebates directly with manufacturers [5]. Their
leverage for doing this comes from each state Medicaid’s pre-
ferred drug list [6]. In addition to the cost of the drug, Medicaid
law allows states to pay a dispensing fee to the pharmacies.
Nevertheless, Federal regulations do not specify its exact
amount, so the dispensing fee that the states pay varies
signiﬁcantly.
Traditionally, Medicaid payments for approximately 400
multisource drugs are subject to Federal upper limits (FUL) set at
150% of the lowest published price for equivalent drugs [5,7].
States also may have their own maximum allowable cost list for
multisource drugs [5].
The 2005 Deﬁcit Reduction Act (DRA) changed the way state
Medicaid programs pay pharmacies from being based on listed
prices AWP and wholesale acquisition cost (WAC) to being based
on the AMP [8]. The DRA set the FUL at 250% of the AMP for
multiple source drugs, as calculated without regard to customary
prompt pay discounts to wholesalers [8]. AMP is deﬁned by DRA
as the average price that a manufacturer receives for a drug in a
given quarter for sales to the retail pharmacy class of trade [8].
According to DRA, the retail pharmacy class of trade is deﬁned
as chain pharmacies, independent pharmacies, mail order phar-
macies, and other outlets that purchase or arrange for the pur-
chase of drugs from a wholesaler or manufacturer [5]. The DRA
AMP regulations have not been implemented to date because of
a preliminary court injunction that enjoins CMS from imple-
menting the ﬁnal rule with comment concerning AMP to the
extent that it affects Medicaid reimbursement rates for outpatient
pharmacy [9].
AMP is expected to be signiﬁcantly lower than the listed
prices [5]. Thus, the change from listed prices to AMP is expected
to decrease Medicaid payments for estimated drug acquisition
costs to pharmacies [10]. Indeed, the average FUL before the
DRA was approximately ﬁve times higher than the proposed
AMP [5]. The AMP was conﬁdential, but such information is
required by DRA to be posted on CMS’s website and made
available to the public and states [8].
The prescription drugs used in institutions such as nursing
homes, hospitals, Intermediate Care Facilities for the Mentally
Retarded, and mental health institutions comprise a signiﬁcant
proportion of overall state drug spending [6]. Most states pay for
these prescription drugs in one of two ways: they may purchase
drugs on a fee-for-service basis, separate from an institutional
payment rate; or they may include drug spending in the bundled
institutional payment rate [6].
The Medicaid Drug Rebate Program
The Medicaid Drug Rebate Program was created by the
Omnibus Reconciliation Act of 1990 (OBRA ’90), which added
Section 1927 to the Social Security Act [8]. OBRA ’90 became
effective in early 1991. The rebate regulations were modiﬁed
by the Medicare Modernization Act (MMA) and DRA. The
Program requires drug manufacturers to enter into a rebate
agreements with the Department of Health and Human Services
in order to receive Federal funding for fee-for-service outpatient
drugs dispensed to Medicaid patients [5,8,11]. Manufacturers
that do not sign a rebate agreement with CMS are not eligible for
Federal Medicaid reimbursement for their products [11].
For innovator drugs, the amount that manufacturers rebate
to Medicaid is the larger of 15.1% of AMP or the difference
between the AMP and the best price per unit and adjusted by the
Consumer Price Index-Urban (CPI-U) [5,12]. The rebate amount
for non-innovator drugs is currently 11% of the AMP per unit
[5,12].
The best price is deﬁned as the lowest manufacturer price
available to private and public purchasers [5,8]. Nevertheless,
drug prices for certain public entities such as the Indian Health
Service, Department of Defense, and Department of Veterans
Affairs are not considered in establishing best prices [8].
According to OBRA ’90 manufacturer rebates were conﬁden-
tial; DRA provisions—not implemented to date—request the
AMP to be disclosed to states and the public. The DRA also has
provisions to secure rebates for certain physician-administered
drugs [8]. It also has provisions regarding the inclusion of autho-
rized generic drugs when calculating the AMP and the best price
for drugs [8].
Medicare Program
Medicare was enacted by Congress in 1965 to provide health
insurance primarily for the nation’s elderly. In 1973, the entitle-
ment was expanded to include certain groups with disabilities or
end stage renal disease. Part A of Medicare provides hospital
inpatient and outpatient services, nursing home care, home
health care, hospice care, and skilled nursing facilities. The hos-
pital inpatient services are paid through a prospective payment
system that covers all services through the diagnostic related
groups.
Medicare Part B covers physician supplies, medical supplies,
some oral cancer therapies, and physician ofﬁce services. Phar-
maceuticals provided in the outpatient setting are paid through
an outpatient prospective payment system (OPPS) and classiﬁed
into ambulatory payment classiﬁcations similar to the inpatient
system. The difference is a drug-speciﬁc payment for outpatient
drugs and pharmaceutical beyond a cost of $55 which is the
threshold to receive separate payments.
Medicare Part C earlier known as Medicare + Choice
(M + C) programs are now known as Medicare Advantage plans
as part of the Medicare Prescription Drug and Modernization
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Act of 2003 (MMA). These were developed by private health
plan sponsors that provide managed Medicare services to enroll-
ees and receive payments from Medicare. The original intent was
to establish and provide access to private plan options similar to
the health maintenance organizations and preferred provider
organizations that operate in a competitive marketplace, reduce
patient cost sharing for Medicare beneﬁts, and cover additional
services that traditional Medicare is not authorized to offer [13].
The Medicare Modernization Act of 2003
The MMA, which was passed in 2003, was designed to provide
access for senior citizens at low prices by encouraging competi-
tion across Medicare drug plan providers. Drug coverage under
Medicare Part D began on January 1, 2006. Medicare Part D
covers prescription drugs and certain related services in the
ambulatory setting. Enrollees pay a premium and participate in
cost sharing. Enrollees may opt for a stand alone prescription
drug plan, known as a Medicare prescription drug plan (PDP) or
through a Medicare Advantage plan, known as a Medicare
Advantage Prescription Drug (MAPD) plan. The plans provide
the drugs through a formulary as approved by CMS. The plans
assume ﬁnancial risk under the conditions established by MMA.
As a result of the fact that net prices include rebates and the fact
that drug companies enter conﬁdential contracts with Medicare
Plans that provide legal conﬁdentiality agreements, there is no
publicly available indicator of the industry’s actual cost [14].
ASP
In response to inﬂationary pressures in spending for Medicare
Part B covered drugs (from $6.5 billion in 2001 to $10.9 billion
in 2004) [15]. The MMA moved from the AWP to the ASP
method of reimbursement for physician-administered drugs. The
ASP-based reimbursement method was instituted by Medicare
beginning in January 1, 2005.
The ASP is based on a computed average transaction price,
i.e., the payments that manufacturers received for their products.
It is the weighted average of all non-Federal sales to wholesalers
and is net of chargeback, discounts, rebates, and other beneﬁts
tied to the purchase of the drug product, whether it is paid to the
wholesaler or the retailer. Of note, there are exceptions to this
general rule. Researchers are invited to refer to these exceptions
listed in the latest ASP quarterly change request document [16].
Nevertheless, ASP is calculated using sales data for all drug
products, branded and generic, available in the market for that
drug. Thus, the ASP for drug products that have generic compe-
tition is very low. The reimbursement rate to providers for single-
source drugs is the lower of 106% of ASP or WAC [17].
Medicare Payment for Cancer Therapies and Biologics
Medicare part B covers certain cancer drugs that have to be
administered in a physician’s ofﬁce [18]. Chemotherapy and
other oncology drug costs are of particular concern to Medicare
because more than 60% of new cancer diagnoses occur in the
elderly. Of the top 20 outpatient drugs that Medicare Part B
covered in 2005, 16 treat cancer or chemotherapy-related side
effects [19]. In the ﬁrst year of Medicare Part D, 16 of the top 20
drugs based upon Medicare expenditure were drugs to treat
cancer or the side effects of chemotherapy [19]. While innovation
is commonly associated with better clinical outcomes and sur-
vival, its ﬁscal burden on payers is considerable. For instance, the
emergence of new drugs on the market for treatment of meta-
static colorectal cancer has been associated with a signiﬁcant
increase in drug costs [20]. In addition to the complexity of
coverage under Part B versus Part D, the shift to ASP pricing had
a signiﬁcant impact on medical oncologists, urologists, rheuma-
tologists, and infectious disease specialists. As of 2006, all end-
stage renal disease drugs, and drugs and biologics with “pass-
through” designation under the OPPS are reimbursed based on
ASP [16].
Patient Cost Sharing andVariation in Coverage
The cost sharing for Medicare beneﬁciaries varies by type of
service, and by the type of plan (e.g., PDP or MAPD that the
beneﬁciary enrolls into), and by the levels and duration of service
received. Medicare Part A is automatic, whereas Part B is
optional and most beneﬁciaries pay a premium and deductible; in
addition, individuals may opt for a Medigap insurance policy,
which covers Medicare eligible expense not reimbursed by Medi-
care. Part D beneﬁciaries who are above the 150% of the Federal
poverty level pay a premium and participate in cost sharing
annually; 25% cost sharing where they initially get partial cov-
erage for their drug costs for up to 75%, followed by 100% cost
sharing because of the gap in coverage when they will pay full
drug costs, and ﬁnally 5% cost-sharing when they reach a set
catastrophic level of maximum coverage for 95% of their drug
costs. Beneﬁciaries below the 150% Federal poverty level include
dual eligible on Medicare and Medicaid and pay lower or no
premiums and lower or no copayments or coinsurance and have
no gap in coverage.
State Medicaid Programs require nominal cost sharing for
prescription drugs for certain patient populations except children
and pregnant women. Cost sharing is also not widely variable as
for Medicare beneﬁciaries. Cost sharing is prohibited for emer-
gency room visits, family planning services and hospice care.
Other Public Programs
A variety of Federal agencies and state and local governments
purchase pharmaceuticals through different procurement
methods, distribution systems and dispensing channels [18–20].
The other public programs account 7% of overall spending for
retail prescription drugs during 2006 [21]. Veteran Affairs,
Department of Defense, Public Health and Coast Guard (The Big
Four) are the largest Federal purchasers of pharmaceuticals aside
from Medicare and Medicaid. In order to provide an integrated,
comprehensive, portable, high quality national drug plan for
Veterans, the VA established the Pharmacy Beneﬁts Management
Strategic Healthcare Group (PBM-SHG) in 1995 [22].
The Federal government publishes several price lists that
apply to the different Federal agencies [23]. These prices apply to
drugs used in community and institutional pharmacy. Federal
Supply Schedule prices are available to all Federal agencies.
Other prices may be restricted to the Big Four or to speciﬁc
Federal agencies. Federal listed prices generally include drug
product and distribution costs.
Federal listed prices may be subject to minimum quantity
purchase. Discounts may be available for prompt payment, and
rebates may be available for formulary placement and market
share. Individual Federal providers may negotiate lower prices
for drugs included in Federal schedules and prices for drugs not
included in those schedules.
Multiple outpatient pharmacy programs operate at the state
level such as workers’ compensation, prisoners, disease speciﬁc
programs (e.g., mental health, HIV/AIDS), and other assistance
programs. States may also manage drug discount programs for
uninsured low income patients. Programs may participate in
intrastate or multistate purchasing pools.
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Local government may also have pharmacy programs at local
health departments, jails, and detention centers, as well as assis-
tance programs for speciﬁc populations.
Section 340B of the Public Health Service Act (340B) pro-
vides manufacturer discounts and rebates for covered outpatient
drugs purchased by certain Federal grantees, state and local
governments, Federally qualiﬁed health center, and qualiﬁed dis-
proportionate share hospitals [24]. 340B prices are based on the
Medicaid fee-for-service Federal rebate; manufacturers may
provide further discounts.
Recommendations
Increasingly, Federal and state governments’ interest in compara-
tive effectiveness and pharmacoeconomic evaluations are
expected to take center stage in the United States for coverage
decisions made by Medicare, Medicaid, and other public payers.
Therefore, these evaluations need to include accurate and unbi-
ased effectiveness and cost estimates from clinical trials and real
world effectiveness studies that are updated to reﬂect Medicare,
Medicaid, or other public payer perspectives and experiences.
With respect to pharmacoeconomic (e.g., cost-effectiveness)
evaluations, our task was to focus narrowly on providing guid-
ance for selecting and using drug cost input parameters for use in
pharmacoeconomic models and evaluations. Recommendations
for pharmacoeconomic evaluations to inform analyses from a
Medicare or Medicaid perspective are summarized in Table 2. A
more detailed list of recommendations follows in this section.
Our recommendations also may apply to budget impact models,
which are increasingly used to support decision-making for pre-
scription drug coverage and beneﬁt design.
The Medicare, Medicaid and other US Government Payers
Subgroup of the ISPOR Task Force on Good Research
Practices—Use of DCTF makes the following recommendations
for research related to drug cost studies:
1. Researchers must be aware of legislation, eligibility and
coverage requirements, and price increases that affect the
actual prices paid for drugs by US government agencies.
Legislation regarding Medicare drug prices includes but is
not limited to information outlined in the MMA of 2003.
Similarly, Medicaid and other governmental agencies have
evolving policies and regulations that inﬂuence the prices
they pay for drugs. Because drug companies and MCOs
enter into conﬁdential contracting arrangements, there are
limited publicly available indicators of actual acquisition
cost (AAC) for pharmaceuticals. We recommend the use of:
• AAC paid by each public program, incorporating any
rebates or discounts, if feasible. When several pro-
grams are evaluated in the economic evaluation, the
weighted average of AAC of the programs should be
estimated.
• ASP for studies of Medicare Part B drugs.
• AMP for studies of Medicaid fee-for-service outpatient
drugs.
• If program-speciﬁc costs are not available, the eco-
nomic evaluation of 340B programs should use Med-
icaid outpatient fee-for-service price net of pharmacy
discounts and Federal rebates to estimate the drug
product cost.
2. Transparency with respect to price inputs is critical. Prices
listed by public programs often exclude dispensing and
administrative costs incurred by pharmacies. An economic
evaluation should estimate and include these costs in the
analysis.
3. The economic evaluation should include the US public pro-
grams’ perspectives in the analysis. Using Medicare as one
example of a public payer, there are multiple viewpoints
(patient, private insurer, and governmental) that are
reﬂected. Different perspectives can lead to sharply different
estimates.
• If the study is conducted from the patient perspective,
the cost in the study should be the estimated out-of-
pocket cost, which should include premiums and
copayments and may include the deductible and like-
lihood of being in the donut hole and/or above the
catastrophic threshold; these factors are dependent
upon the type of plan in which the patient is enrolled.
• If the study perspective is the private insurer adminis-
tering the beneﬁt, the cost should be AAC plus dis-
pensing and administrative fees less estimated patient
cost sharing. The cost will differ according to beneﬁt
structure because the cost to the plan would be differ-
ent before and after patients spending more than the
deductibles, reaching the donut hole, or within the
range of catastrophic coverage.
• The government’s perspective should include all drug
payments, regardless of source.
4. Drug costs for a Medicare study should consider whether
the drug is covered under Parts A, B, C and/or Part D. The
status of coverage would affect the relevant costs. Also, the
likelihood of coverage and tier status, when applicable,
should be incorporated into drug cost estimates.
5. With the advent of Medicare part D prescription data
becoming available for Government and academic research-
ers, it is imperative that investigators understand the limi-
tations of the data. Emerging Data on Medicare Part D for
Table 2 Standard recommendations for pharmacoeconomic studies from Medicare and Medicaid perspectives
Feature Medicare Medicaid
1. Perspectives for
Pharmacoeconomic
evaluations to inform cost
containment
Medicare perspective, patient’s perspective Federal and State Medicaid perspective, patient’s perspective
2. Cost and Effectiveness
considerations for
decision-analytic methods
1. Use actual acquisition cost (AAC) paid by each public program, incorporating any rebates or discounts;ASP for
Medicare Part B drugs;AMP for Medicaid fee-for-service outpatient drugs; Medicaid outpatient fee-for-service price net of
pharmacy discounts and Federal rebates
2. Include dispensing and administrative costs incurred by pharmacies and plans
3. Consider Budget impact analysis = cost analysis from the payer’s perspective
4. Include effects of estimated acquisition cost (AWP minus discount,ASP,AMP), rebates, type of plan, beneﬁt structure/tier
status, generic drug (multisource drug) prices, and patients’ real-world adherence in sensitivity analyses
AWP, average wholesale price;ASP, average sales price;AMP, average manufacturer price.
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Calendar Year 2006 should be used with caution as this was
the ﬁrst year that the drug beneﬁt was administered and
CMS has stated that the data for later years (i.e., 2007 and
beyond) may be more valid and reliable for research pur-
poses. For Medicare parts A, B and D, the investigator must
understand the link between disease and resource use as it
pertains to the way the beneﬁt is administered.
6. Special attention has to be paid to cancer and other high
cost drugs, particularly when the drug costs are a signiﬁcant
proportion of total health-care expenditures for a disease
state. Medicare Part D has unique implication for cancer
patients because some cancer drugs were already covered
under Medicare Part B. Researchers should be kept abreast
of new data that are available at the CMS website. Refer to
the series of announcements regarding Medicare payment
and coding for drugs and biologicals in the “Downloads”
section of the ASP “Overview” page at: the following
address: http://www.cms.hhs.gov/McrPartBDrugAvgSales
Price/.
7. Weighted average drug cost across Medicaid delivery
systems (fee-for-service and managed care; other Medicaid
programs and dual eligible), and dispensing channels (hos-
pital, long-term care, physician ofﬁces and outpatient clinics,
outpatient pharmacy) should be presented when feasible.
8. Fee-for-service Medicaid pharmacy reimbursement should
include an estimated average of drug acquisition cost and
dispensing fee. FUL and state maximum allowable cost
limits for multiple source drugs should be considered in the
analysis. Federal and state rebates should be deducted from
the pharmacy reimbursement amount to estimate the net
drug product cost. Differences in calculation of innovator
and multisource products rebates should be considered in
the analysis.
9. Managed care recommendations should apply to Medicaid
managed care. Medicare recommendations should apply for
dual eligible beneﬁciaries, with exception of the payments
made by the Medicaid program in substitution of dual
eligible patients.
10. In general, adjustments for inﬂation should use the Con-
sumer Price Index (CPI) All Urban Consumers for Prescrip-
tion drugs. Exceptions occur in public programs. AMP of
innovator drugs purchased by the Medicaid program
should be adjusted by the CPI All Urban Consumers for All
Items values based on launch date and current quarter
AMP—42 U.S.C. 1396r-8(c)(2)(A)(ii)(II). Also drug pro-
curement contracts of other public programs typically limit
cost increases to the CPI All Urban All Items.
11. Budgetary impact analysis for private health plans partici-
pating in public programs will become increasingly popular
and important in the future, therefore, it is critical that
guidelines speciﬁc to this demand be developed.
12. Due to the possible wide variation in drug prices, producers
of studies need to document the credible source(s) of their
drug cost inputs.
13. Drug costs should be consistent with the time frame of
the study. For example, if the time frame of the study is
the lifetime of patients, drug costs should be calculated
accordingly.
14. Due to the variation in coverage and beneﬁt structure across
plans, sensitivity analyses are warranted. When it comes to
sensitivity analyses, the following should be taken into
account:
• AAC, rebates and discounts
• For Medicare studies, variation in coverage based on
drug costs under MMA, including the “standard”
Medicare beneﬁt of 25% copay for initial drug expen-
ditures, 100% of cost in the donut hole where there is
a gap in coverage, and then 5% copay during cata-
strophic coverage
• The likelihood of coverage across different Plans and
tier status for the drug should be speciﬁed
• Due to the high proportion of total health-care costs
attributable to drug costs among certain extremely ill
patients (e.g., terminally ill cancer patients), the pro-
portion of such terminally or severely ill patients
should also be considered
• The effect of generic prices when brand-name drugs
are off-patent or likely to be off-patent should be
incorporated.
Source of ﬁnancial support: None.
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